CD200R signaling in tumor tolerance and inflammation: A tricky balance

Current Opinion in Immunology

Volumn 24, Issue 2, 2012, Pages 233-238

  Rygiel, Tomasz P ^a   Meyaard, Linde ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD200 ANTIGEN; CD200 MONOCLONAL ANTIBODY; CD200 RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; CANCER CELL CULTURE; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIGENS, SURFACE; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; NEOPLASMS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 84859162348     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2012.01.002     Document Type: Review

References (46)

1. de Visser K.E. Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both?. Cancer Immunol Immunother 2008, 57:1531-1539.
2. Barclay A.N., Clark M.J., McCaughan G.W. Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure. Biochem Soc Symp 1986, 51:149-157.
3. Broderick C., Hoek R.M., Forrester J.V., Liversidge J., Sedgwick J.D., Dick A.D. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Am J Pathol 2002, 161:1669-1677.
4. Barclay A.N., Wright G.J., Brooke G., Brown M.H. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol 2002, 23:285-290.
5. Preston S., Wright G.J., Starr K., Barclay A.N., Brown M.H. The leukocyte/neuron cell surface antigen OX2 binds to a ligand on macrophages. Eur J Immmunol 1997, 27:1911-1918.
6. Wright G.J., Cherwinski H., Foster-Cuevas M., Brooke G., Puklavec M.J., Bigler M., Song Y., Jenmalm M., Gorman D., McClanahan T., et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 2003, 171:3034-3046.
7. Rijkers E.S.K., De Ruiter T., Baridi A., Veninga H., Hoek R.M., Meyaard L. The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes. Mol Immunol 2008, 45:1126-1135.
8. Hatherley D., Cherwinski H., Moshref M., Barclay A.N. Recombinant CD200 protein does not bind activating proteins closely related to CD200 receptor. J Immunol 2005, 175:2469-2474.
9. Zhang S., Cherwinski H., Sedgwick J.D., Phillips J.H. Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol 2004, 173:6786-6793.
10. Zhang S., Phillips J.H. Identification of tyrosine residues crucial for CD200R-mediated inhibition of mast cell activation. J Leukoc Biol 2006, 79:363-368.
11. Costello D.A., Lyons A., Denieffe S., Browne T.C., Cox F.F., Lynch M.A. Long term potentiation is impaired in membrane glycoprotein CD200-deficient mice: a role for toll-like receptor activation. J Biol Chem 2011, 286:34722-34732.
12. Mihrshahi R., Barclay A.N., Brown M.H. Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells. J Immunol 2009, 183:4879-4886.
13. Hoek R.M., Ruuls S.R., Murphy C.A., Wright G.J., Goddard R., Zurawski S.M., Blom B., Homola M.E., Streit W.J., Brown M.H., et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000, 290:1768-1771.
14. Rosenblum M.D., Olasz E.B., Yancey K.B., Woodliff J.E., Lazarova Z., Gerber K.A., Truitt R.L. Expression of CD200 on epithelial cells of the murine hair follicle: a role in tissue-specific immune tolerance?. J Invest Dermatol 2004, 123:880-887.
15. Snelgrove R.J., Goulding J., Didierlaurent A.M., Lyonga D., Vekaria S., Edwards L., Gwyer E., Sedgwick J.D., Barclay A.N., Hussell T. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol 2008, 9:1074-1083.
16. Rygiel T.P., Rijkers E.S., de R.T., Stolte E.H., van d V., Rimmelzwaan G.F., Boon L., van Loon A.M., Coenjaerts F.E., Hoek R.M., et al. Lack of CD200 enhances pathological T cell responses during influenza infection. J Immunol 2009, 183:1990-1996.
17. Mukhopadhyay S., Pluddemann A., Hoe J.C., Williams K.J., Varin A., Makepeace K., Aknin M.L., Bowdish D.M., Smale S.T., Barclay A.N., Gordon S. Immune inhibitory ligand CD200 induction by TLRs and NLRs limits macrophage activation to protect the host from meningococcal septicemia. Cell Host Microbe 2010, 8:236-247.
18. Goulding J., Godlee A., Vekaria S., Hilty M., Snelgrove R., Hussell T. Lowering the threshold of lung innate immune cell activation alters susceptibility to secondary bacterial superinfection. J Infect Dis 2011, 204:1086-1094.
19. Kretz-Rommel A., Bowdish K.S. Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression. Expert Opin Biol Ther 2008, 8:5-15.
20. Ohyama M., Terunuma A., Tock C.L., Radonovich M.F., Pise-Masison C.A., Hopping S.B., Brady J.N., Udey M.C., Vogel J.C. Characterization and isolation of stem cell-enriched human hair follicle bulge cells. J Clin Invest 2006, 116:249-260.
21. Tang C., Lee A.S., Volkmer J.P., Sahoo D., Nag D., Mosley A.R., Inlay M.A., Ardehali R., Chavez S.L., Pera R.R., et al. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol 2011, 29:829-834.
22. Kelly O.G., Chan M.Y., Martinson L.A., Kadoya K., Ostertag T.M., Ross K.G., Richardson M., Carpenter M.K., D'Amour K.A., Kroon E., et al. Cell-surface markers for the isolation of pancreatic cell types derived from human embryonic stem cells. Nat Biotechnol 2011, 29:750-756.
23. Garza L.A., Yang C.C., Zhao T., Blatt H.B., Lee M., He H., Stanton D.C., Carrasco L., Spiegel J.H., Tobias J.W., Cotsarelis G. Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells. J Clin Invest 2011, 121:613-622.
24. Kawasaki B.T., Mistree T., Hurt E.M., Kalathur M., Farrar W.L. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun 2007, 364:778-782.
25. Kawasaki B.T., Farrar W.L. Cancer stem cells, CD200 and immunoevasion. Trends Immunol 2008, 29:464-468.
26. Tonks A., Hills R., White P., Rosie B., Mills K.I., Burnett A.K., Darley R.L. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007, 21:566-568.
27. Moreaux J., Hose D., Reme T., Jourdan E., Hundemer M., Legouffe E., Moine P., Bourin P., Moos M., Corre J., et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006, 108:4194-4197.
28. McWhirter J.R., Kretz-Rommel A., Saven A., Maruyama T., Potter K.N., Mockridge C.I., Ravey E.P., Qin F., Bowdish K.S. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 2006, 103:1041-1046.
29. Brunetti L., Di N.R., Abate G., Gorrese M., Gravetti A., Raia M., Scalia G., Pascariello C., Camera A., Del V.L. CD200/OX2, a cell surface molecule with immuno-regulatory function, is consistently expressed on hairy cell leukaemia neoplastic cells. Br J Haematol 2009, 145:665-667.
30. Siva A., Xin H., Qin F., Oltean D., Bowdish K.S., Kretz-Rommel A. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother 2008, 57:987-996.
31. Moreaux J., Veyrune J.L., Reme T., De V.J., Klein B. CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun 2008, 366:117-122.
32. Stumpfova M., Ratner D., Desciak E.B., Eliezri Y.D., Owens D.M. The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma. Cancer Res 2010, 70:2962-2972.
33. Gorczynski R.M., Chen Z., Diao J., Khatri I., Wong K., Yu K., Behnke J. Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. Breast Cancer Res Treat 2009.
34. Coles S.J., Wang E.C., Man S., Hills R.K., Burnett A.K., Tonks A., Darley R.L. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 2011, 25:792-799.
35. Pallasch C.P., Ulbrich S., Brinker R., Hallek M., Uger R.A., Wendtner C.M. Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leuk Res 2009, 33:460-464.
36. Wang L., Liu J.Q., Talebian F., El-Omrani H.Y., Khattabi M., Yu L., Bai X.F. Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy. Eur J Immunol 2010, 40:2569-2579.
37. Petermann K.B., Rozenberg G.I., Zedek D., Groben P., McKinnon K., Buehler C., Kim W.Y., Shields J.M., Penland S., Bear J.E., et al. CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 2007, 117:3922-3929.
38. Wong K.K., Khatri I., Shaha S., Spaner D.E., Gorczynski R.M. The role of CD200 in immunity to B cell lymphoma. J Leukoc Biol 2010, 88:361-372.
39. Jenmalm M., Cherwinski H., Bowman E., Phillips J.H., Sedgwick J.D. Regulation of myeloid cell function through the CD200 receptor. J Immunol 2006, 176:191-199.
40. Gorczynski R.M., Clark D.A., Erin N., Khatri I. Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice. Breast Cancer Res Treat 2011, 130:49-60.
41. Rygiel T.P., Karnam G., Goverse G., van der Marel A.P., Greuter M.J., van Schaarenburg R.A., Visser W.F., Brenkman A.B., Molenaar R., Hoek R.M., et al. CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor. Oncogene 2011.
42. Copland D.A., Calder C.J., Raveney B.J., Nicholson L.B., Phillips J., Cherwinski H., Jenmalm M., Sedgwick J.D., Dick A.D. Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. Am J Pathol 2007, 171:580-588.
43. Gorczynski R.M., Chen Z., Hu J., Kai Y., Lei J. Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice. Clin Exp Immunol 2001, 126:220-229.
44. Kretz-Rommel A., Qin F., Dakappagari N., Ravey E.P., McWhirter J., Oltean D., Frederickson S., Maruyama T., Wild M.A., Nolan M.J., et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 2007, 178:5595-5605.
45. Kretz-Rommel A., Qin F., Dakappagari N., Cofiell R., Faas S.J., Bowdish K.S. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol 2008, 180:699-705.
46. Di Giacomo A.M., Biagioli M., Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010, 37:499-507.